ArticleCureus2025
Triglyceride-Glucose Index and Atherogenic Index as Alternative Biomarkers for Glycemic Control in Type 2 Diabetes Mellitus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does diabetes status modify the association between the triglyceride-glucose index and major adverse cardiovascular events in patients with coronary heart disease? A systematic review and meta-analysis of longitudinal cohort studies.Cardiovascular diabetology · 2025Pooled it
- Lifestyle Adherence and Metabolic Control in Adults with Type 2 Diabetes: Development of a Lifestyle Compliance Index.Diagnostics (Basel, Switzerland) · 2026Article
- The Shared IL-12/IL-35 p35 Subunit Is Associated With Heightened Atherogenic Risk in African Patients With Type 2 Diabetes.Endocrinology, diabetes & metabolism · 2026Article
- Association of Nontraditional Lipid Indices With Poor Glycemic Control in Patients With Type 2 Diabetes: A Cross-Sectional Study.Journal of diabetes research · 2026Article
- Association between atherogenic index of plasma and sepsis in critically ill patients with ischemic stroke: a retrospective cohort study using propensity score and machine learning approaches.Lipids in health and disease · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe triglyceride-glucose (TyG) index and the atherogenic index (AI) are emerging biomarkers that have been gaining attention in diabetes management as alternatives for assessing glycemic control in clinical settings. Since direct measurement of insulin resistance is impractical in routine care, it offers a more accessible alternative with potential broad clinical application. The TyG index and AI can serve as useful substitute biomarkers and could help in the management of glycemic control in type 2 diabetes mellitus (T2DM). METHODOLOGY: A cross-sectional study was conducted with 200 T2DM participants, divided into two groups: 100 with good glycemic control (<7.0%) and 100 with poor control (≥7.0%), based on HbA1c levels. Lipid profile and HbA1c were measured using Chem-7 (Erba Mannheim, India) and Insta Check semi-auto analyzers. TyG index, TyG-body mass index (BMI), and TyG-waist circumference (WC) were calculated using standard formulas. Statistical analysis was performed by using SPSS 20.0 (IBM Corp., Armonk, New York, US), with p < 0.05 considered statistically significant.
resultsAmong 200 subjects, 63% were men and 37% were women. The mean age for type 2 diabetes subjects is 61.24 ± 7.25 years. The mean level of the TyG index in poor glycemic control is significantly higher (30.36 ± 5.51, p < 0.001) than that of good glycemic control (4.06 ± 0.05, p < 0.001). A significant positive correlation was observed between the TyG index and poor glycemic control. The TyG index has good predictive ability in poor glycemic control (area under the curve (AUC): 0.88; 95% confidence interval (CI): 0.83-0.92). The TyG optimal cutoff is ≥5.22 with 78.22% sensitivity and 94.06% specificity.
conclusionThe TyG index shows a significant correlation with glycemic control and could serve as a valuable supportive marker for T2DM, particularly in smaller clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.